In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as AptaBio Therapeutics has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
KOSDAQ:A293780 - Analysts future estimates and past financials data (KRW Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
3/31/2026
4,273
-20,212
-16,750
-16,718
N/A
12/31/2025
3,698
-16,346
-15,335
-15,276
N/A
9/30/2025
3,441
-20,227
-15,669
-15,377
N/A
6/30/2025
3,108
-25,185
-14,941
-14,662
N/A
3/31/2025
3,106
-27,991
-16,527
-16,250
N/A
12/31/2024
3,361
-29,378
-12,400
-12,160
N/A
9/30/2024
2,906
-20,170
-17,147
-16,000
N/A
6/30/2024
2,055
-16,236
-17,049
-15,761
N/A
3/31/2024
942
-11,365
-14,812
-13,469
N/A
12/31/2023
324
-11,866
-15,487
-14,095
N/A
9/30/2023
53
-13,289
-8,744
-8,138
N/A
12/31/2022
48
-10,565
-7,884
-6,833
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A293780's forecast earnings growth is above the savings rate (3.1%).
Earnings vs Market: Insufficient data to determine if A293780's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A293780's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if A293780's revenue is forecast to grow faster than the KR market.
High Growth Revenue: Insufficient data to determine if A293780's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A293780's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/19 09:14
End of Day Share Price
2026/06/19 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AptaBio Therapeutics Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.